Floatz logo

mk-3475

Clear Cell Renal Carcinoma

Arkadiusz Z. Dudek, MDmonoclonal_antibodyPhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

24 Active assets in the Clear Cell Renal Carcinoma cohort.

Asset / SponsorPhaseRating
Everolimus
Peking University First Hospital
Phase 2BB
Axitinib
University of California, San Francisco
Phase 3B
Nivolumab
Exelixis
Phase 2B
gw786034
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 2B
Belzutifan
José Claudio Casali da Rocha
Phase 2B

View all 39 →

Same molecule, other indications

mk-3475 is also rated in:

melanomaDormant
B
Indicative ·
61 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
60 / 100
View asset →
MSI Positive Non-Colorectal CancersDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →